Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
China NT Pharma Group CoHKSE:01011 -6.67%1 EV-to-FCF is -152.37 as of Sep. 02, 2026. GuruFocus rates HKSE:01011 with a GF Score™ of 1/100. The stock has 4 warning signs investors should review. Among 566 Drug Manufacturers companies, China NT Pharma Group Co ranks worse than 176678.27% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, China NT Pharma Group Co's Enterprise Value is HK$872.92 Mil.
China NT Pharma Group Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-5.73 Mil. Therefore, China NT Pharma Group Co's EV-to-FCF for today is -152.37.
The historical rank and industry rank for China NT Pharma Group Co's EV-to-FCF or its related term are showing as below:
HKSE:01011'
s EV-to-FCF Range Over the Past 10 Years
Min: -159.86 Med: -6.93 Max: 458.55
Current: -151.58
During the past 13 years, the highest EV-to-FCF of China NT Pharma Group Co was 458.55. The lowest was -159.86. And the median was -6.93.
HKSE:01011's EV-to-FCF is ranked worse than 100% of 566
companies
in the Drug Manufacturers industry
Industry Median: 19.82
vs HKSE:01011: -151.58
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
China NT Pharma Group Co (HKSE:01011) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
China NT Pharma Group Co's PE Ratio (TTM) for today is calculated as:
China NT Pharma Group Co's share price for today is HK$0.42.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. China NT Pharma Group Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-0.039.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
China NT Pharma Group Co EV-to-FCF Related Terms
China NT Pharma Group Co EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, China NT Pharma Group Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China NT Pharma Group Co EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, China NT Pharma Group Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where China NT Pharma Group Co's EV-to-FCF falls into.
China NT Pharma Group Co's current Enterprise Value is HK$872.92 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. China NT Pharma Group Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-5.73 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China NT Pharma Group Co (HKSE:01011) has a EV-to-FCF of -152.37 as of Sep. 02, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on China NT Pharma Group Co and its competitors. According to the industry distribution chart, China NT Pharma Group Co ranks #999999 out of 566 companies in the Drug Manufacturers industry.
Is China NT Pharma Group Co's EV-to-FCF too high?
China NT Pharma Group Co's current EV-to-FCF is -152.37. Based on the distribution chart, China NT Pharma Group Co ranks #999999 out of 566 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, China NT Pharma Group Co has a GF Score™ of 1/100, reflecting its overall financial health beyond just this single metric.
How does China NT Pharma Group Co's EV-to-FCF compare to ZTS?
According to the Drug Manufacturers industry distribution chart, China NT Pharma Group Co ranks #999999 out of 566 companies for EV-to-FCF. This places China NT Pharma Group Co in the lower half of its industry. The industry median EV-to-FCF is 19.82. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 19.82, based on 566 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on China NT Pharma Group Co and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 19.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China NT Pharma Group Co's current EV-to-FCF is -152.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China NT Pharma Group Co stock overvalued right now?
China NT Pharma Group Co (HKSE:01011) has a current EV-to-FCF of -152.37. The current EV-to-FCF is -152.37. China NT Pharma Group Co's overall GF Score™ is 1/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For China NT Pharma Group Co (HKSE:01011), the current EV-to-FCF is -152.37 as of Sep. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
China NT Pharma Group Co Ltd is a technology-based pharmaceutical company. It is engaged in research and development, production, and sale of private-label drugs, as well as the provision of pharmaceutical marketing and promotion services in China. It focused on the research, development, production, and sales of orthopedic, psychiatric, and oncology drugs. The Group's operations are regarded as having two operating and reportable segments, namely Agency Services and Healthcare Related Services. The company generates maximum of its revenue from Healthcare Related Services.
1GF Score
Get the complete analysis for HKSE:01011
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:01011 has been successfully added to your 
